21 May 2013
Keywords: Merck & Co, Niancin, Laropiprant, Tredaptive, Heart attack, Stroke, Oxford University
Article | 11 March 2013
Adding extended-release (ER) niacin to statins does not reduce the chances of high risk patients having a heart attack or ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 March 2013
20 May 2013
© 2013 thepharmaletter.com